𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Overview of Pharmacology and Clinical Trials Program with the Zotarolimus-Eluting Endeavor Stent

✍ Scribed by DAVID E. KANDZARI; MARTIN B. LEON

Book ID
109216670
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
152 KB
Volume
19
Category
Article
ISSN
0896-4327

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Five-year clinical follow-up after impla
Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study
✍ Ian T. Meredith; John Ormiston; Robert Whitbourn; I. Patrick Kay; David Muller; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract Objective: To evaluate the 5‐year clinical outcomes of patients treated with the Endeavor zotarolimus‐eluting stent (ZES) in the ENDEAVOR I first‐in‐human study. Background: ENDEAVOR I was a prospective, nonrandomized, multicenter study of the Endeavor ZES in 100 consecutive patients wi

Improved Late Clinical Safety With Zotar
Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial
✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB
Late-Term Clinical Outcomes With Zotarol
Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB